Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos
Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) and US pharma major Eli Lilly (NYSE: LLY) have failed in their attempt to overturn a combined $9 billion punitive damage award by a US jury for hiding cancer risks associated with their diabetes drug Actos (pioglitazone), according to a court ruling last week.
US District Judge Rebecca Doherty of the Western District of Louisiana said that plaintiffs have pointed to sufficient evidence from which the jury could have concluded that the 'information' about bladder cancer contained in Actos labels did not adequately warn of the increased risk of cancer.
In the original court decision (The Pharma Letter April 8), Takeda was to pay $6 billion and Lilly $3 billion, but Lilly, which co-promoted Actos with Takeda from 1999 to 2006, said that under its agreement with Takeda, it will be indemnified by the Japanese firm for its losses and expenses with respect to the US litigation and other related expenses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze